会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明授权
    • Method of preparing botulinum neurotoxin type E light chain
    • 制备肉毒杆菌神经毒素E型轻链的方法
    • US07833524B2
    • 2010-11-16
    • US12273157
    • 2008-11-18
    • Eric A. JohnsonMarite BradshawMichael BaldwinJoseph T. Barbieri
    • Eric A. JohnsonMarite BradshawMichael BaldwinJoseph T. Barbieri
    • C12P1/04
    • C07K14/33
    • The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1-425 and expressing a polypeptide.
    • 本发明提供了A型或E型轻链型肉毒杆菌毒素的制备方法,其中所述制剂既具有催化活性,又具有可溶性。 优选地,制剂基本上由A型肉毒毒素轻链的氨基酸残基1至425组成。还提供了筛选抑制剂的方法,其中所述方法包括将测试抑制剂暴露于A型轻链A型肉毒杆菌毒素的制备 评估制剂的生物活性。 在另一个实施方案中,提供了提供A型肉毒毒素轻链的催化活性可溶性制剂的方法,其中所述方法包括获得包含编码氨基酸残基1-425的DNA序列并表达多肽的表达载体。
    • 14. 发明授权
    • Method for preparing botulinum neurotoxin type A light chain
    • 制备肉毒杆菌神经毒素A型轻链的方法
    • US07465457B2
    • 2008-12-16
    • US11404289
    • 2006-04-14
    • Eric A. JohnsonMarite BradshawMichael BaldwinJoseph T. Barbieri
    • Eric A. JohnsonMarite BradshawMichael BaldwinJoseph T. Barbieri
    • A61K39/08C12P21/02
    • C07K14/33
    • The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1-425 and expressing a polypeptide.
    • 本发明提供了A型或E型轻链型肉毒杆菌毒素的制备方法,其中所述制剂既具有催化活性,又具有可溶性。 优选地,制剂基本上由A型肉毒毒素轻链的氨基酸残基1至425组成。还提供了筛选抑制剂的方法,其中所述方法包括将测试抑制剂暴露于A型轻链A型肉毒杆菌毒素的制备 评估制剂的生物活性。 在另一个实施方案中,提供了提供A型肉毒毒素轻链的催化活性可溶性制剂的方法,其中所述方法包括获得包含编码氨基酸残基1-425的DNA序列并表达多肽的表达载体。
    • 17. 发明申请
    • Method of preparing botulinum neurotoxin type A light chain
    • 制备肉毒杆菌神经毒素A型轻链的方法
    • US20060258847A1
    • 2006-11-16
    • US11404289
    • 2006-04-14
    • Eric JohnsonMarite BradshawMichael BaldwinJoseph Barbieri
    • Eric JohnsonMarite BradshawMichael BaldwinJoseph Barbieri
    • C07K14/00C07K1/00C07K17/00
    • C07K14/33
    • The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1-425 and expressing a polypeptide.
    • 本发明提供了A型或E型轻链型肉毒杆菌毒素的制备方法,其中所述制剂既具有催化活性,又具有可溶性。 优选地,制剂基本上由A型肉毒毒素轻链的氨基酸残基1至425组成。还提供了筛选抑制剂的方法,其中所述方法包括将测试抑制剂暴露于A型轻链A型肉毒杆菌毒素的制备 评估制剂的生物活性。 在另一个实施方案中,提供了提供A型肉毒毒素轻链的催化活性可溶性制剂的方法,其中所述方法包括获得包含编码氨基酸残基1〜425的DNA序列并表达多肽的表达载体。
    • 18. 发明申请
    • Application internationalization using dynamic proxies
    • 使用动态代理的应用程序国际化
    • US20050050548A1
    • 2005-03-03
    • US10650880
    • 2003-08-28
    • Joseph SheinisMichael BaldwinAlexander Sherkin
    • Joseph SheinisMichael BaldwinAlexander Sherkin
    • G06F9/00G06F9/42G06F9/44
    • G06F9/4488G06F9/4486G06F9/454G06F2209/542
    • An application that was not internationalized when coded may be internationalized through the addition of interception and localization logic and tables without modification of the original application logic. The interception logic may be configured to intercept calls to an application component and invoke localization logic in response to an intercepted call to the application component. The interception logic may use dynamic proxies to intercept method calls from a client component to an application component both before and after the execution of the method. The interception logic may use JAVA reflection to determine whether input parameters or return values associated with the method call are localizable. The application component logic may operate on data stored in a primary database table in which the data is represented in the system default locale.
    • 编码时未国际化的应用程序可以通过添加拦截和本地化逻辑和表来进行国际化,而不会修改原始应用程序逻辑。 截取逻辑可以被配置为截取对应用组件的调用并且响应于被截取的对应用组件的调用来调用定位逻辑。 截取逻辑可以使用动态代理在方法执行之前和之后拦截从客户端组件到应用程序组件的方法调用。 拦截逻辑可以使用JAVA反射来确定与方法调用相关联的输入参数或返回值是否可本地化。 应用程序组件逻辑可以对存储在主数据库表中的数据进行操作,其中数据在系统默认语言环境中被表示。